Can Medical Cannabis Affect Opioid Use?
CompletedNCT06206252
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this observational study is to learn how medical cannabis (MC) affects pain and the use of opioid pain medications. Participants who have chronic pain and use prescribed opioid pain medication will opt-in to using MC or not for the 3-month study. Participants who are certified in Pennsylvania will purchase specific medical cannabis products at a reduced cost from a partnering medical cannabis dispensary monthly. All participants will complete baseline, daily, and monthly assessments to observe changes across groups.
Study details
- Official title
- The Effect of Medical Cannabis on Opioid Use for Individuals With Chronic Pain
- Conditions
- Interventions
- Other: Medical Cannabis
- Sponsor
- Thomas Jefferson University
- Start date
- 2023-09-07
- Primary completion
- 2025-12-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Current diagnosis of chronic, intractable pain * Use of prescription opioids for longer than 90 days * Have a smartphone or agree to use one provided * English fluency * Medical cannabis group only: Willing to get certified by a physician to use medical cannabis in PA OR already certified but have not been using medical cannabis products regularly (daily or weekly) for longer than 30 days * Medical cannabis group only: Willing to accept a temporary restriction on medical cannabis products * Control group: Agree to continue not using cannabis for the duration of the study (3 months) Exclusion Criteria: * Under 18 years old * Being under conservatorship * Self-reported pregnant or breastfeeding * Cannabis Use Disorder * Active treatment in methadone or buprenorphine program for Opioid Use Disorder * Diabetic neuropathy or chemotherapy-induced neuropathy alone * Medical cannabis group: Cannabis use (daily/weekly) for more than 30 days * Control group: Cannabis Use
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06206252